UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 23, 2026

December 6, 2025

ORIC Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-39269	47-1787157
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
(State or other jurisdictionof incorporation)	(CommissionFile Number)	(IRS EmployerIdentification No.)

240 E. Grand Ave, 2nd Floor

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)

(650) 388-5600

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

     Title of each class

      Trading Symbol(s)

     Name of each 
exchange on which registered

     Common stock, par value $0.0001 per share

     ORIC

     The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒ ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ ☐

Item 82.0102 ~~Other~~Results ~~Events~~of Operations and Financial Condition.

On February 23, 2026, ORIC Pharmaceuticals, Inc. (the “Company”), ~~presented~~issued ana ~~enozertinib~~press ~~(ORIC-114)~~release ~~program~~announcing ~~update~~its ~~(the~~financial ~~“Program~~results ~~Update”)~~for onthe ~~December 6,~~fourth ~~2025.~~quarter ~~The~~and ~~Program~~full ~~Update~~year ~~covered~~ended ~~recently~~December ~~announced~~31, ~~data from the Company’s Phase 1b trial of enozertinib~~2025. A ~~presentation~~copy ~~containing~~of the ~~data~~press ~~presented~~release ~~in the Program Update~~ is attached hereto as Exhibit 99.1 ~~hereto~~ and is incorporated herein by reference.

All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
Exhibit No.		Description
99.1		~~Presentation~~Press Release dated February 23, 2026
104		Cover Page Interactive Data File (embedded ~~within~~with the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ORIC PHARMACEUTICALS, INC.

Date: December 8, 2025

/s/ Christian V. Kuhlen

Date: February 23, 2026

/s/ Dominic Piscitelli

Christian V. Kuhlen, M.D., J.D.

Dominic PiscitelliChief Financial Officer

General Counsel

Filing Compare · Oric Pharmaceuticals, Inc.